Aceclofenac/eperisone controlled-release - NavipharmAlternative Names: Aceclofenac/eperisone SR; Eperisone controlled-release/aceclofenac; Eperisone SR/aceclofenac; NVP-1203
Latest Information Update: 06 Apr 2016
At a glance
- Originator Navipharm
- Class Esters; Muscle relaxants; Neuroprotectants; Nonsteroidal anti-inflammatories; Phenylacetates; Piperidines; Propiophenones; Small molecules
- Mechanism of Action Calcium channel antagonists; Cyclooxygenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Back pain
Most Recent Events
- 09 Nov 2014 Preclinical trials in Back pain in South Korea (PO)
- 09 Nov 2014 Navipharm plans two phase I pharmacokinetics trials for Healthy volunteers in South Korea (NCT02289404 and NCT02289274)